The prescription drug affordability crisis in America has prompted various solutions from both the private sector and government initiatives. Two notable approaches are Mark Cuban’s Cost Plus Drugs and Trump Rx—a series of drug pricing policies. While both aim to address medication costs, they differ fundamentally in scope, effectiveness, and accessibility. More importantly, Trump Rx has significant limitations that make it an insufficient solution for many Americans, particularly those requiring mental health medications.

Mark Cuban’s CostPlus Drugs: Transparency and Real Savings

Launched in 2022, CostPlus Drugs revolutionized pharmaceutical retail through radical pricing transparency. The model is straightforward: medications are sold at manufacturer cost plus a flat 15% markup, plus $3 pharmacy fee and $5 shipping for mail orders.

How CostPlus Drugs Works

Complete Price Transparency: Unlike traditional pharmacies where costs are obscured through pharmacy benefit managers and rebate systems, every customer can see the exact breakdown:

• Manufacturer cost
• 15% markup
• All associated fees

Direct-to-Consumer Model: By operating online and eliminating intermediaries, CostPlus Drugs passes savings directly to consumers. A medication that costs $400 at a traditional pharmacy might cost $30-50 through CostPlus.

No Insurance Required: The platform often provides lower costs than insurance copays. This is revolutionary for uninsured Americans and those with high-deductible plans.

Extensive Generic Formulary: Over 800 FDA-approved generic medications covering common treatments for diabetes, hypertension, infections, and mental health conditions.

Real-World Impact: The savings are dramatic. Metformin, fluoxetine, and other common generics show 80-90% cost reductions compared to retail prices.

Trump Rx: Government Policy Approach with Significant Limitations

Trump Rx represents a suite of executive actions and regulatory initiatives aimed at reducing drug prices through government intervention. However, the approach has critical gaps that limit its effectiveness.

Key Components and Their Limitations

Most Favored Nation (MFN) Pricing

• Theory: Tie Medicare Part B drug prices to lower international prices
• Limitation: Only affects Medicare Part B drugs; excludes the majority of Americans on private insurance or Part D
• Reality: Many essential medications simply aren’t available under Medicare Part B

Rebate Reform

• Theory: Redirect PBM rebates to consumers at point of sale
• Limitation: Complex implementation; doesn’t address the underlying cost of brand-name drugs
• Reality: Partially implemented and inconsistent across states

Insulin Price Cap ($35/month)

• Positive: One concrete policy with measurable impact for diabetic patients
• Limitation: Only addresses insulin; excludes other critical medications

Drug Price Transparency in Advertising

• Theory: List prices in TV ads create market pressure
• Limitation: List prices are often meaningless; actual negotiated prices vary widely
• Reality: Doesn’t translate to lower out-of-pocket costs for most consumers

The Critical Mental Health Medication Gap

Here’s where Trump Rx fails most visibly: Mental health medications for ADHD and OCD are largely not covered under Medicare Part B and are frequently excluded or heavily restricted under Trump Rx policies, particularly for working-age adults.

Why This Matters

ADHD Medications: Common treatments like:

• Adderall (amphetamine/dextroamphetamine)
• Ritalin (methylphenidate)
• Concerta
• Strattera

These are essential for millions of American workers and students but are notably absent from Trump Rx’s targeted interventions. For those requiring these medications, Trump Rx offers no relief—leaving them entirely dependent on private insurance negotiation or paying full price.

OCD Medications: Treatments like:

• Sertraline (Zoloft)
• Fluoxetine (Prozac)
• Paroxetine (Paxil)
• Higher-dose formulations required for OCD treatment

While some of these exist as generics, Trump Rx doesn’t prioritize them, and insurance coverage remains unpredictable and expensive.

The Disparity

A person with Type 2 diabetes might see insulin costs capped at $35/month under Trump Rx. But a person with severe ADHD or OCD requiring medication for work productivity might pay $100-300+ monthly for the same medication that CostPlus Drugs offers for $15-30.

Direct Comparison: CostPlus Drugs vs Trump Rx

Aspect	CostPlus Drugs	Trump Rx
Scope	All Americans with any prescription	Primarily Medicare/Medicaid beneficiaries
Generic Medications	800+ with transparent pricing	Limited focus on specific drugs
Brand-Name Drugs	Not offered	Some targeted interventions
ADHD Medications	Available at low cost	No targeted support
OCD Medications	Available at low cost	No targeted support
Mental Health Coverage	Comprehensive	Minimal to non-existent
Implementation Speed	Immediate	Delayed, blocked by litigation
Sustainability	Market-driven, durable	Policy-dependent, reversible
Working-Age Adults	Fully supported	Limited support

Why This Distinction Matters

Trump Rx is politically popular because it addresses visible issues like insulin costs and targets the Medicare population (politically powerful demographic). However, it ignores significant populations:

• Working-age adults with ADHD: Face unaffordable medication costs despite needing them for employment
• People with OCD requiring higher doses: Excluded from cost relief initiatives
• Those on private insurance: Largely unaffected by Trump Rx policies
• Uninsured Americans: Must rely entirely on market solutions like CostPlus Drugs

The Real-World Impact

A typical scenario:

• Under Trump Rx: A 72-year-old Medicare beneficiary with diabetes sees insulin costs capped. A 35-year-old with ADHD on private insurance still pays $150+ monthly for Adderall. Both exist in the same healthcare system, but only one receives targeted government help.
• With CostPlus Drugs: Both individuals can access their medications at transparent, dramatically reduced prices. The 35-year-old gets Adderall for ~$20/month, the 72-year-old can also access cheaper insulin alternatives.

The Complementary Reality

While Trump Rx addresses specific political priorities, it leaves massive gaps. CostPlus Drugs doesn’t have these gaps—it serves anyone with a prescription for a generic medication, regardless of age, insurance status, or political demographic.

For mental health medications specifically, CostPlus Drugs is often the only accessible solution for uninsured or underinsured Americans, since Trump Rx actively ignores this category.

Conclusion

Mark Cuban’s CostPlus Drugs represents a more comprehensive and equitable approach to medication affordability. While Trump Rx brings attention to drug pricing and helps specific populations with specific drugs, it leaves critical gaps—particularly in mental health treatment.

The hard truth: If you have ADHD or OCD and aren’t covered by generous insurance or Medicare, Trump Rx offers you nothing. CostPlus Drugs might offer you access to affordable treatment. That difference is life-changing for millions of Americans struggling with these conditions while trying to maintain employment and financial stability.

Rather than viewing policy interventions as sufficient, Americans should recognize that market transparency and direct-to-consumer models like CostPlus Drugs may be more reliable than government initiatives that cover specific drugs for specific populations while ignoring others entirely.